聚焦学术前沿，38项最新科学研究即将公布，2024 ACC热点抢鲜看！

401-06 - A Double-blind, Randomized Placebo Procedure-controlled Trial Of An Interatrial Shunt In Patients With HfrEF And HfpEF: Principal Results From The RELIEVE-HF Trial

RELIVE-HF试验主要结果：HFrEF和HFpEF患者使用V-Wave心房分流的双盲随机安慰假手术对照试验

401-08 - Empagliflozin After Acute Myocardial Infarction: Results Of The EMPACT-MI Trial

EMPACT-MI试验结果：恩格列净对伴或不伴糖尿病、曾发生过心肌梗死的成人患者全因死亡率和因心衰住院的影响

401-10 - CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results

AEGIS-II（载脂蛋白A-I减少缺血性综合征患者事件II）试验主要结果：CSL112（载脂蛋白A-I）输注与急性心肌梗死患者的心血管结局

405-08 - Effect Of Gamification, Financial Incentives Or Both Combined To Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial

BE-ACTIVE随机临床试验：游戏化、经济激励或二者结合对主要心血管不良事件风险升高患者增加体育活动的影响

405-10 - Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 Kardia-2 Study

KARDIA-2研究主要结果：全球性2期研究，评估Zilebesiran（一种皮下给药的靶向血管紧张素原的RNAi疗法）联合标准治疗对高血压控制不充分患者的降压作用

延伸阅读>>>

一针管半年！Ⅰ、Ⅱ期研究结果均提示，长效降压药Zilebesiran疗效和安全性较好

405-12 - Efficacy And Safety Of Olezarsen In Patients With Hypertriglyceridemia And High Cardiovascular Risk: Primary Results Of The BRIDGE-TIMI 73a Trial

BRIDGE-TIMI 73a试验的主要结果：Olezaresen治疗高甘油三酯血症合并高心血管风险患者的疗效和安全性

405-14 - Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

一项随机、双盲、安慰剂对照3期研究，在心血管疾病或心血管风险极高危或高危患者中，评估稳定降脂治疗基础上使用Lerodalcibep（三代PCSK9抑制剂，针对PCSK9的融合蛋白）治疗的长期疗效和安全性

405-16 - Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound And Durable Reductions In APOC-3 And Triglycerides (TG) In Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results

SHASTA-2最终结果：在严重高甘油三酯血症（SHTG）患者中，研究性RNAi治疗药物Plozasiran（ARO-APC3）显著、持久降低APOC-3和甘油三酯水平

406-08 - Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement In Patients With Small Aortic Annuli: Primary Outcomes From The Randomized Smart Trial

SMART随机试验主要结果：小主动脉瓣环患者中，评估自膨胀vs.球囊扩张TAVR

406-10 - Effect Of Edetate Disodium Based Chelation Infusions On Cardiovascular Events In Post-MI Patients With Diabetes: The TACT2 Trial

TACT2试验：输注依地酸二钠螯合剂对心肌梗死后糖尿病患者心血管事件的影响

406-12 - Long-term Beta-blocker Treatment After Acute Myocardial Infarction And Preserved Left Ventricular Ejection Fraction - The REDUCE-AMI Trial

REDUCE-AMI试验：急性心肌梗死后左心室射血分数保留患者长期β受体阻滞剂治疗的作用

406-14 - Percutaneous Transvalvular Micro-axial Flow Pump In Infarct Related Cardiogenic Shock. Results Of The Danger-shock Trial

DANGER-SHOCK试验结果：经皮跨瓣膜微型轴流泵治疗梗死相关心源性休克

406-16 - One-month Ticagrelor Monotherapy After Pci In Acute Coronary Syndromes: Principal Results From The Double-blind, Placebo-controlled Ultimate Dapt Trial

ULTIMATE DAPT试验的主要结果：一项双盲、安慰剂对照试验，评估急性冠状动脉综合征PCI术后一个月替格瑞洛单药治疗

411-08 - A Selective Aldose Reductase Inhibitor (at-001) For The Treatment Of Diabetic Cardiomyopathy: Primary Results Of The Phase 3 Randomized Controlled Arise-hf Study

ARISE-HF研究主要结果：3期随机对照试验，评估选择性醛糖还原酶抑制剂AT-001治疗糖尿病性心肌病的作用

411-10 - Efficacy And Safety Of Ninerafaxstat, A Novel Cardiac Mitotrope, In Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results Of IMPROVE-HCM

IMPROVE-HCM研究的结果：新型心脏线粒体和部分脂肪酸氧化（pFOX）抑制剂Ninerafaxstat治疗症状性非梗阻性肥厚型心肌病的疗效和安全性

411-12 - Topical Tranexamic Acid To Reduce Seizures In Cardiac Surgery

局部使用氨甲环酸减少心脏手术中的癫痫发作

411-14 - Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT)

PROACT研究：一项3期随机、开放标签、盲终点、优势试验，在乳腺癌和淋巴瘤患者中评估依那普利预防蒽环类药物心脏毒性的效果

411-16 - Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial

TACTiC试验：技术辅助非处方瑞舒伐他汀给药后的结果

412-08 - Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC)

ORBITA-COSMIC随机安慰剂对照试验：冠状窦减缩窄装置治疗难治性心绞痛

412-10 - Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial

DEDICATE-ZHK6随机试验1年结果：中低风险患者经导管主动脉瓣植入术与外科主动脉瓣置换术的比较

412-12 - Effect Of Alcohol-mediated Renal Denervation On Blood Pressure In The Presence Of Antihypertensive Drugs: 3-month Primary Results From The Target Bp I Randomized Trial

TARGET BP I随机试验3个月主要结果：服用降压药患者接受酒精介导的经皮去肾神经术对血压的影响

412-14 - Preventive PCI Or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques

预防性PCI或单独药物治疗动脉粥样硬化性冠状动脉易损斑块

412-16 - Comparison Of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty For The Outcomes Of Drug-coated Balloon In The Treatment Of Femoropopliteal Artery Disease

血管内超声引导vs.血管造影引导下药物涂层球囊血管成形术治疗股腘动脉疾病的结果

403-08 - Comparison Of An “Inclisiran First” Strategy With Usual Care In Patients With Atherosclerotic Cardiovascular Disease: Results From The VICTORION-INITIATE Randomized Trial

VICTORION-INITIATE随机试验结果：动脉粥样硬化性心血管疾病患者采用“英克司兰优先”策略与常规治疗的比较

403-10 - Targeting Weight Loss To Personalize The Prevention Of Type 2 Diabetes

以减肥为目标，个性化预防2型糖尿病

403-12 - Once-weekly Semaglutide In Patients With Heart Failure With Preserved Ejection Fraction, Obesity And Type 2 Diabetes: Main Results From The Step-hfpef Dm Trial

STEP-HFpEF-DM试验主要结果：全球多中心、随机、双盲、安慰剂对照试验，评估在标准治疗基础上每周一次司美格鲁肽vs安慰剂治疗HFpEF合并肥胖和2型糖尿病患者的疗效

403-14 - Mandibular Advancement Device Versus CPAP For Blood Pressure Reduction In Obstructive Sleep Apnea And High Cardiovascular Risk─ A Randomized Clinical Non-inferiority Trial

一项随机临床非劣效性试验，评估下颌推进装置 vs. 持续气道正压通气（CPAP）在阻塞性睡眠呼吸暂停合并心血管高危患者中的降压作用

403-16 - Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-acute Coronary Syndrome (TELE-ACS)

TELE-ACS研究：急性冠状动脉综合征后心血管高危患者的远程急性评估

407-08 - Benzodiazepine-free Cardiac Anesthesia For Reduction Of Postoperative Delirium (B-Free): A Multi-centre Randomized Cluster Crossover Trial

B-FREE多中心随机分组交叉试验：无苯二氮卓类药物的心脏麻醉减少术后谵妄的作用

407-10 - The Diabetes Remote Intervention To Improve Use Of Evidence-based Medications (drive) Study: A Randomized Evaluation Of A Team-based Remote Education And Medication Management Program To Reduce Cv And Kidney Risk

糖尿病远程干预改善循证药物的使用研究（DRIVE研究）：一项随机试验，评估基于团队的远程教育和药物管理计划在降低心血管和肾脏风险的效果

407-12 - Improving Cardiac Rehabilitation Participation In Lower-socioeconomic Status Patients: Case Management Vs. Financial Incentives

提高社会经济地位较低患者的心脏康复参与度：病例管理vs.经济激励

407-14 - Impact Of Routine Assessment Of Patient-Reported Health Status In Heart Failure Clinic (PRO-HF) Trial

PRO-HF试验：心力衰竭临床试验中患者报告健康状况常规评估的影响

407-16 - Restrictive Versus Liberal Blood Transfusion Strategy In Type 1 Versus Type 2 Myocardial Infarction: A Prespecified Subgroup Analysis From The Myocardial Ischemia And Transfusion (mint) Trial

心肌缺血和输血（MINT）试验预先指定亚组分析：1型vs. 2型心肌梗死患者中，限制性vs.自由性输血策略的比较

413-08 - Fractional Flow Reserve-guided Complete Or Culprit-only PCI In Patients With ST-elevation Myocardial Infarction

ST段抬高型心梗患者FFR引导下完全PCI vs.仅罪犯血管PCI

413-10 - A Multicenter Prospective Randomized Study Comparing The Incidence Of Periprocedural Cerebral Embolisms Caused By Catheter Ablation Of Atrial Fibrillation Between Cryoballoon And Radiofrequency Ablation

一项多中心前瞻性随机研究，比较冷冻球囊消融vs.射频消融治疗房颤围手术期脑栓塞的发生率

413-12 - Transseptal Versus Retrograde Aortic Ventricular Entry To Reduce Systemic Emboli (the TRAVERSE Trial)

TRAVERSE试验：经中隔vs.逆行主动脉心室入路减少体循环栓塞

413-14 - Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention In Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, Ivus-acs Trial

IVUS-ACS试验：一项多中心、随机、盲法试验，评估急性冠状动脉综合征患者血管内超声引导vs.血管造影引导下经皮冠状动脉介入治疗

413-16 - Protein And Exercise To Reverse Frailty In Older Men And Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial

PERFORM-TAVR试验：接受经导管主动脉瓣置换术的老年男性和女性中，蛋白质和运动逆转虚弱效果